ClinicalTrials.gg
RecruitingNCT06794658GluCaaringUpdated Jul 31, 2025

EFFICACY OF REMOTE MONITORING OF PATIENTS WITH DIABETES UNDER INSULIN TREATMENT, BY USING Caaring SOFTWARE

An interventional study of software in Diabetes Mellitus, sponsored by Persei Vivarium. Recruiting at 2 sites in Spain. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Persei Vivarium · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.

Planned enrollment
135th of 211
200 · median 394
Started
2024
with 9 others
No phase
65 of 254
11 open now
Primary completion
2025-09
later than 7 of 28 live
Registered
238th of 254
by date

Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 135th largest by planned enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2024, is one of 65 with no phase, reaches primary completion later than 7 of the 28 other live ones, and was the 238th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 254 studies in Diabetes Mellitus with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial investigation with device is to determinate the efficacy of the remote monitoring in insulin-treated diabetic patients with a software called Caaring®.

The main question it aims to answer is if the development of a self-management platform (Caaring®) that enhances the role of the patient with diabetes in the course of their disease will increase the TIR and/or reduce the number of in-person and telephone visits assisted by specialized medical and nursing personnel.

This is two arms, randomized study. Online telemonitoring group: The follow-up of these patients will be carried out prospectively remotely through the Caaring® platform. And Retrospective Control group: The data of these patients are collected retrospectively from the last 12 weeks prior to their inclusion.

Researchers will compare the assessments between the two groups to see if the software Caaring® improve the TIR and/or reduce the number of visits to the specialist personnel.

Participants with diabetes will:

Use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems. In addition,

Control group patients must have clinical and glucometry data from the 12 weeks prior to their inclusion date available in the Medical Record, and/or through the monitoring platforms of the continuous glucose monitoring devices Caaring group patients must have sufficient technological skills to use a smartphone.

Read the detailed description

This is a longitudinal, comparative non-inferiority, multicenter, with 2 arms Medical Device Clinical Trial.

The protocol and informed consent documents have been reviewed and approved by the hospital human subjects reviewboard and the study will be performed in accordance with the Declaration of Helsinki

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Diabetes Mellitus (DM)
  • Remote patient monitoring
  • glycemic control
  • Caaring
  • Time in Range (TIR)
  • Online telemonitoring
  • Digital Health
  • DTx
  • PROMs
  • Patient-reported data
  • real-world data
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with diabetes mellitus treated with insulin.
  • Patients treated with subcutaneous insulin in multiple daily doses or patients treated with subcutaneous insulin in continuous subcutaneous infusion systems
  • Patients using a glucose monitoring system
  • Patients who are able to complete the study questionnaires
  • is obtained from the patient.
  • For Control group: Patients must have clinical and glucometry data from the 12 weeks prior to their inclusion date available in the Medical Record, and/or through the monitoring platforms of the continuous glucose monitoring devices - For Caaring group: Patients must have sufficient technological skills to use a smartphone.

Exclusion criteria

Exclusion Criteria:

  • Patients with cognitive or sensory difficulties or with insufficient command of Spanish who, in the opinion of the investigator, makes it difficult to understand the questions or the scales, as long as they do not have a legally authorized representative capable of participating in the study.
  • Transient patients in whom it may be anticipated that follow-up will not be completed due to a change of residence.
  • Patients Who are participating at the time of recruitment in any other clinical trial. Participation in observational studies will not be an exclusion criteria.
  • Patients whose main diagnosis is a poorly controlled mental disorders or other medical illness.
  • Patients with terminal illness and/or in palliative care according to the criteria of the SECPAL (Spanish Society of Palliative Care).
  • Institutionalized patients
  • Patients who are pregnant or breastfeeding.
  • Patients whose inclusion is not considered advisable by the investigator's assessment due to they are under specific follow-up in other hospital units (hemodialysis, transplants, etc.) that require mandatory hospital attendance less frequently than once every two months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Online telemonitoring group (G_CAARING)

    The monitoring and control of these patients will be carried out remotely through the Caaring® platform. Patients will connect to an APP on a mobile phone. They will have to complete the data and questionnaires related to the study variables.

    Device: software

  • No intervention
    Retrospective Control group

    The data of these patients are collected retrospectively from the medical history, from the last 12 weeks prior to their inclusion.

Interventions

  • Devicesoftware

    Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to diabetes.

    Also known as: Caaring

06

What researchers measure

Primary outcomes

  1. Determinate the efficacy of the remote monitoring in insulin-treated diabetic patients with a software called Caaring®.

    % acceptable Time in Range (TIR) of glucose measurements defined as the percentage of how long the patient's glucose value was within the target range (70-180 mg/dL)

    Time frame: 12 weeks

Secondary outcomes

  1. PROs. Changes in Health-related quality of life (HRQOL): EsDQOL

    Change in the patient's quality of life scale the study compared to baseline: EsDQOL questionnaire for adults (Value 0-100). A higher score reflects a higher health-related quality of life (HRQoL).

    Time frame: Day 0 and week 12

  2. PROs. in Health-related quality of life (HRQOL): KINDL

    Change in the patient's quality of life scale the study compared to baseline: KINDL and Diabetes-related quality of life questionnaire for pediatrics for the pediatric population (Value 0-100). A higher score reflects a higher health-related quality of life (HRQoL).

    Time frame: Day 0 and week 12

  3. PROs. Patient satisfaction with the software Caaring

    The patient satisfaction will be measured through a specific satisfaction questionnaire created for this purpose. (Value 3-15). A higher score reflects greater satisfaction with software care.

    Time frame: Week 12

  4. PROs. Variation in clinical parameters of glycemic control: HbA1c

    Variation in clinical parameters of glycemic control, HbA1c

    Time frame: Day 0 and Week 12

  5. PROs. Variation in clinical parameters of glycemic control, HbA1c and CGM data: TIR

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: TIR (time in range)(70-180 mg/dl)

    Time frame: Day 0 and Biweekly up to 12 weeks

  6. PROs. Variation in clinical parameters of glycemic control, HbA1c and CGM data: TBR

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: TBR (time below range) Time \< 70 mg/dL

    Time frame: Day 0 and Biweekly up to 12 weeks

  7. PROs. Variation in clinical parameters of glycemic control, HbA1c and CGM data: TIT

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: TIT (Time in target range), (70-140 mg/dL).

    Time frame: Day 0 and Biweekly up to 12 weeks

  8. PROs. Variation in clinical parameters of glycemic control, HbA1c and CGM data: CV

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: CV (Coefficient of Variation)

    Time frame: Day 0 and Biweekly up to 12 weeks

  9. PROs. Variation in clinical parameters of glycemic control, HbA1c and CGM data: GRI

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: GRI (Glycemic Risk Index).

    Time frame: Day 0 and Biweekly up to 12 weeks

  10. PROs. Number of Medical Visits

    Number of medical visits, calls or interactions with specialist healthcare personnel

    Time frame: Day 0 and Monthly up to 12 weeks

  11. PROs. Adherence of treatment

    Adherence to therapy (insulin)

    Time frame: Day 0 and Weekly up to 12 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2025, 9 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 9 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 27, 2025
StartActual
Dec 11, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06794658
Lead sponsor
Persei Vivarium
Collaborators
Effice Servicios Para la Investigacion S.L.
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Dec 11, 2024
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Jul 31, 2025

Study contacts

Patricia Dominguez
Contact
patricia.dominguez@perseivivarium.com
+34 915 004 013
Roberto Bravo
Contact
roberto.bravo@perseivivarium.com
+34 915 004 013

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion